Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

Stopped early

Conditions studied: Granulomatosis With Polyangiitis, Microscopic Polyangiitis

In brief

Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. This study proposes to follow patients who were enrolled in the RAVE study to determine if treatment with rituximab influences long-term outcomes.

Key facts

Study ID

NCT01586858

Run by

Johns Hopkins University

People needed

67

Starts

2012-05-01

Expected to finish

2014-05-15

Last updated by the study team

2017-10-27

Who can join

Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrollment in the RAVE trial
• Completion of RAVE Common Closeout Date visit
• Informed consent

You may not qualify if…

• Refusal to participate
• Inability to comply with standard-of-care, including routine clinical visits and testing.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Boston University — Boston, Massachusetts, United States
• Mayo Clinic Foundation — Rochester, Minnesota, United States
• Hospital for Special Surgery — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• The Cleveland Clinic — Cleveland, Ohio, United States
• University Hospital Groningen — Groningen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.